InvestLog
Back to Market返回行情

APUS Apimeds Pharmaceuticals US, Inc

AMEXHealthcare
$4.28-5.93%ClosedMarket Cap: $6.5M

As of 2026-08-17 16:00

Why APUS matters now

Apimeds Pharmaceuticals US, Inc (APUS) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.28 with -5.93% on the session and $6.5M in market capitalization.

The latest indexable market news headline is "NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency Exchange" from GlobeNewsWire.

Latest News

NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency ExchangeGlobeNewsWire · 2026-08-03
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in OctoberGlobeNewsWire · 2026-07-28
For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® CertificationPRNewsWire · 2026-06-08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

AMEX

Beta

0.15

Apimeds Pharmaceuticals US, Inc. (APUS) functions as a clinical-stage biopharmaceutical firm operating within the United States. This company is dedicated to the entire lifecycle of its flagship product, Apitox – from its initial investigation and development to its production, market introduction, and sales. Apitox, a key active pharmaceutical ingredient, is specifically designed to alleviate inflammation and manage pain symptoms experienced by individuals suffering from osteoarthritis and multiple sclerosis. Established in 2020, APUS has its corporate headquarters situated in Hopewell, New Jersey, and operates as a subsidiary of Api Meds, Inc.